Grant: Idea to Innovation
McMaster University
$125,000.00
Validation and scale up of vaccine stabilization for ambient handling using a pullulan/trehalose
FY 2016-17
Summary
Developing a technique for safely storing and transporting vaccines is considered the ""holy grail"" in global health, with huge potential for positive social impact. Current systems rely on ""cold"" supply chains that are expensive, heavily regulated and require a stable source of energy, to ensure that vaccines are always transported, handled, and stored at controlled temperatures. However, these requirements greatly limit the market access of vaccines, especially to the world's most remote and impoverished regions, while greatly increasing manufacturing costs. Today, our goal is to revolutionize how vaccines are handled. Our team has experimented with a pullulan/trehalose formulation that, once added, encapsulates molecules and protects them from environmental conditions (heat, oxygen). This will allow sensitive reagents - such as vaccines - to be transported and stored at ambient conditions. We have developed a proof-of-concept (in vitro only) using the herpes simplex virus (HSV) as a model system; this performance is a strong proof of concept as HSV, in principle, is more difficult to stabilize relative to other viruses due to its enveloped structure. The goal of this project is to expand the commercial value of our pullulan/trehalose stabilizing technology by a) validating performance in vivo b) assessing technology's ability to stabilize different types of vaccines c) developing scale up and implementation procedures for successful user adoption. All research efforts are directed towards the goal of positioning our technology as an engineering solution and a platform for vaccine stabilization. Our proposed method is easy to use while keeping vaccination procedures the same, does not require extensive capital costs or additional manufacturing steps, and will not require external source of energy during storage or transportation. With cost reduction benefits, combined with the value of solving a global health equity challenge, this technology has great potential for commercial success.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
500188-2016
Name nom
Filipe, Carlos
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
1
Nb partie
1
Application title
Validation and scale up of vaccine stabilization for ambient handling using a pullulan/trehalose
Keyword
NSERC
Application summary
Developing a technique for safely storing and transporting vaccines is considered the ""holy grail"" in global health, with huge potential for positive social impact. Current systems rely on ""cold"" supply chains that are expensive, heavily regulated and require a stable source of energy, to ensure that vaccines are always transported, handled, and stored at controlled temperatures. However, these requirements greatly limit the market access of vaccines, especially to the world's most remote and impoverished regions, while greatly increasing manufacturing costs. Today, our goal is to revolutionize how vaccines are handled. Our team has experimented with a pullulan/trehalose formulation that, once added, encapsulates molecules and protects them from environmental conditions (heat, oxygen). This will allow sensitive reagents - such as vaccines - to be transported and stored at ambient conditions. We have developed a proof-of-concept (in vitro only) using the herpes simplex virus (HSV) as a model system; this performance is a strong proof of concept as HSV, in principle, is more difficult to stabilize relative to other viruses due to its enveloped structure. The goal of this project is to expand the commercial value of our pullulan/trehalose stabilizing technology by a) validating performance in vivo b) assessing technology's ability to stabilize different types of vaccines c) developing scale up and implementation procedures for successful user adoption. All research efforts are directed towards the goal of positioning our technology as an engineering solution and a platform for vaccine stabilization. Our proposed method is easy to use while keeping vaccination procedures the same, does not require extensive capital costs or additional manufacturing steps, and will not require external source of energy during storage or transportation. With cost reduction benefits, combined with the value of solving a global health equity challenge, this technology has great potential for commercial success.